MAR 13, 2015 7:16 AM PDT

Stem Cells Lurking in Tumors Can Resist Treatment​​​​

WRITTEN BY: Judy O'Rourke
Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment. Malignant tumors contain stem cells, prompting worries among medical experts that the cells' transformative powers help cancers escape treatment.

New research proves that the threat posed by cancer stem cells is more prevalent than previously thought. Until now, stem cells had been identified only in aggressive, fast-growing tumors. But a mouse study at Washington University School of Medicine in St Louis shows that slow-growing tumors also have treatment-resistant stem cells.
Brain tumor stem cells (orange) in mice express a stem cell marker (green). Researchers are studying how cancer stem cells make tumors harder to kill and are looking for ways to eradicate these treatment-resistant cells.
The low-grade brain cancer stem cells identified by the scientists also were less sensitive to anticancer drugs. By comparing healthy stem cells with stem cells from these brain tumors, the researchers discovered the reasons behind treatment resistance, pointing to new therapeutic strategies.

"At the very least, we're going to have to use different drugs and different, likely higher dosages to make sure we kill these tumor stem cells," says senior author David H. Gutmann, MD, PhD, the Donald O. Schnuck Family Professor of Neurology.

First author Yi-Hsien Chen, PhD, a senior postdoctoral research associate in Gutmann's laboratory, used a mouse model of neurofibromatosis type 1 (NF1) low-grade brain tumors to identify cancer stem cells and demonstrate that they could form tumors when transplanted into normal, cancer-free mice.

NF1 is a genetic disorder that affects about 1 in every 2,500 babies. The condition can cause an array of problems, including brain tumors, impaired vision, learning disabilities, behavioral problems, heart defects, and bone deformities.

The most common brain tumor in children with NF1 is the optic glioma. Treatment for NF1-related optic gliomas often includes drugs that inhibit a cell growth pathway originally identified by Gutmann. In laboratory tests conducted as part of the new research, it took 10 times the dosage of these drugs to kill the low-grade cancer stem cells.

Compared with healthy stem cells from the brain, the cancer stem cells made more copies of a protein called Abcg1 that helps those cells survive stress.

"This protein blocks a signal from inside the cells that should make them more vulnerable to treatment," Gutmann says. "If we can identify a drug that disables this protein, it would make some cancer stem cells easier to kill."

Although the mice the researchers studied were bred to model NF1 optic gliomas, the researchers said the findings could be applied more broadly to other brain tumors.

"Because stem cells haven't differentiated into specialized cells, they can easily activate genes to turn on new developmental programs that allow the cells to survive cancer treatments," says Gutmann, who directs the Washington University Neurofibromatosis Center. "Based on these new findings, we will have to develop additional strategies to keep these tumors from evading our best treatments."

The research, which appears online in Cell Reports, is titled "Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties."

[Source: Washington University in St Louis]
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
NOV 12, 2020
Immunology
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
NOV 12, 2020
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
Nutrition is essential to health; what we eat in our daily diet affects our overall health condition and what diseases w ...
NOV 17, 2020
Clinical & Molecular DX
Tumor Stiffness Linked to Its Aggressiveness
NOV 17, 2020
Tumor Stiffness Linked to Its Aggressiveness
  As tumors grow, tiny areas at their cores are found to become stiff prior to metastasis, or the spread of cancer ...
Loading Comments...